Ivermectin for COVID-19 prophylaxis

Hegazy AA, Hegazy RA. COVID- 19: Virology, pathogenesis and potential therapeutics. Afro-Egypt J Infect Endem Dis. 2020;10(2):93-99.

Shouman WM. Prophylactic ivermectin in COVID-19 contacts; ClinicalTrials.gov (2020). Available at: https://clinicaltrials.gov/ct2/show/NCT04422561 (Accessed June 10, 2021)

Shouman WM, Nafae RM, Hegazy AA, et al. Use of ivermectin as a prophylactic option in asymptomatic family close contacts for patients with COVID-19 (2020). Available at: https://clinicaltrials.gov/ProvidedDocs/61/NCT04422561/Prot_SAP_000.pdf (Accessed June 10, 2021)

Shouman WM, Hegazy AA, Nafae RM, et al. Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomized Clinical Trial. J Clin Diagnostic Res. 2021;15(2):27-32.

Hegazy AA, Alghamdi MS, Shouman WM, Hegazy RA. Mass Chemoprophylaxis with Ivermectin against COVID-19 Pandemic: Review and Authors’ Perspective. Acta Scient Med Sci. 2021;5(6):47-51.

Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216.

Chamie-Quintero J, Hibberd JA, Scheim D. Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p=. 002 for effect by state, then 13-fold increase after ivermectin use restricted. 2021;1-13. doi:10.31219/osf.io/9egh4

Ramírez C, Herrera-Paz EF, Peralta G, et al. Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis? EClinicalMedicine. 2021;32:100744.

Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122-1133.

Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. EClinicalMedicine. 2021;37:100959.

Nobmann S, Bauer B, Fricker G. Ivermectin excretion by isolated functionally intact brain endothelial capillaries. Br J Pharmacol. 2001;132(3):722-728.

Nicolas P, Maia MF, Bassat Q, et al. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. Lancet Glob Health. 2020;8(1):e92-e100.

Levy M, Martin L, Bursztejn AC, et al. Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study. Br J Dermatol. 2020;182(4):1003-1006.

Hope J. Ivermectin saves India | Letter to the Editor. 2021; Available at: https://www.thedesertreview.com/opinion/letters_to_editor/ivermectin-saves-india/article_14b1f1d6-cd2f-11eb-8b78-9710d864f627.html (Accessed June 12, 2021)

Lind JN, Lovegrove MC, Geller AI, et al. Increase in Outpatient Ivermectin Dispensing in the US During the COVID-19 Pandemic: A Cross-Sectional Analysis. J Gen Intern Med. 2021:1–3. doi:10.1007/s11606-021-06948-6

Mathias J. Use of ivermectin for prevention, treatment of COVID-19. 2021; Available at: https://www.ormanager.com/briefs/use-of-ivermectin-for-prevention-treatment-of-covid-19/ (Accessed June 15, 2021)

Abreu JL. Ivermectin for the prevention of COVID-19. So…WHO is telling the Truth? Daena: Int J Good Cons. 2020;A2.15(2)1-30.

Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.

Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. J Antibiot (Tokyo). 2021:1–13. doi:10.1038/s41429-021-00430-5

Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 18; 9 July 2021. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1000678/Variants_of_Concern_VOC_Technical_Briefing_18.pdf

Speare R, Durrheim D. Mass treatment with ivermectin: an underutilized public health strategy. Bull World Health Organ. 2004;82(8):562.

Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021. doi:10.1097/MJT.0000000000001402

de Melo GD, Lazarini F, Larrous F, et al. Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin. EMBO Mol Med. 2021;25:e14122.

Fox 40. Front line COVID-19 critical care alliance to Japanese Olympic Committee: The Tokyo Olympic Games Can Go on Safely. 2021; Available at: https://www.wicz.com/story/44037795/front-line-covid-19-critical-care-alliance-to-japanese-olympic-committee-the-tokyo-olympic-games-can-go-on-safely

Full fact. Ivermectin for Covid-19 remains controversial. 2021; Available at: https://fullfact.org/health/ivermectin-covid-treatment/

Morgenstern J, Redondo JN, Olavarría Á, et al. Retrospective cohort study of Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in Healthcare Workers. MedRxiv. 2021. doi:10.1101/2021.04.10.21255248

Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2021;28(3):e299.